If you have been reading about somatotroph and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-02-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | G-protein-coupled receptor on pituitary somatotrophs |
| Half-life, long-acting form | Several days | Extended by covalent albumin binding |
| Half-life, short form | About 30 minutes | Cleared rapidly by peptidases and kidneys |
| Route in studies | Subcutaneous injection | Used in the published human trials |
| Main measured effect | Rise in GH and IGF-1 | Surrogate markers rather than clinical endpoints |
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
== Pharmacokinetics == Absorption: Once consumed, cefuroxime axetil is converted to the active compound cefuroxime by esterases of mucosal cells in the gastrointestinal tract. Cefuroxime is then released for systematic circulation. If cefuroxime axetil is given with food, absorption values can increase from 37% in fasting patients to 52% in fed patients. Distribution: It has been reported that after cefuroxime axetil administration, it can be found in tonsil tissue, sinus tissue, bronchial tissue and middle ear effusion. Elimination: After cefuroxime production, the body is unable to metabolize the drug, and is eliminated unchanged in the urine.
== Biochemistry == The entire genome has recently been sequenced, and promoter libraries have been developed for both conditional and constitutive gene expression, adding to the utility of L. plantarum. It is also commonly employed as the indicative organism in niacin bioassay experiments, in particular, AOAC International Official Method 944.13, as it is a niacin auxotroph.
Delay lines are used to incubate droplets on-chip. After formation, droplets can be introduced into a serpentine channel with length of up to a meter or more. Increasing the depth and width of the delay line channel (as compared to channels used to form and transport droplets) enables longer incubation times while minimizing channel back pressure. Because of the larger channel size, droplets fill up the delay line channel and incubate in the time it takes the droplets to traverse this channel. Delay lines were originally designed for incubating droplets containing chemical reaction mixtures and were capable of achieving delay times of up to one hour. These devices make use of delay line channels tens of centimeters in length. Increasing the total length of the delay line channels to one or more meters made incubation times of 12 or more hours possible. Delay lines have been shown to maintain droplet stability for up to 3 days, and cell viability has been demonstrated using on-chip delay lines for up to 12 hours. Prior to the development of delay lines, on-chip incubation was performed by directing droplets into large reservoirs (several millimeters in both length and width), which offers high storage capacity and lower complexity of device construction and operation if precise time control of droplets is not required.
=== Legal status === Somapacitan was approved for medical use in the United States in August 2020. The U.S. Food and Drug Administration (FDA) granted the approval of Sogroya to Novo Nordisk, Inc. In January 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Sogroya, intended for the treatment of growth hormone deficiency in adults. The applicant for this medicinal product is Novo Nordisk A/S. Somapacitan was approved for medical use in the European Union in March 2021.
Sources: en.wikipedia.org
Experiments confirm that UV-B light is necessary for parietin synthesis—under controlled conditions, thalli exposed only to photosynthetically active radiation (PAR) regenerated 12% of their parietin, while those exposed to UV-B restored 35%. Despite lower UV-B levels in Arctic environments, X. parietina maintains high parietin concentrations, suggesting that additional environmental factors regulate its production. Seasonal field studies show that parietin levels in Xanthoria parietina follow an annual cycle. In naturally occurring populations, concentrations were lowest in winter and nearly doubled by the summer solstice. This pattern mirrors seasonal shifts in UV-B radiation, suggesting that parietin synthesis is rapidly upregulated in spring to shield the photobiont from excess light and declines more gradually in autumn as irradiance decreases. In addition to parietin, X. parietina produces several related anthraquinones, including fallacinol (also called teloschistin), fallacinal, emodin, and parietinic acid. Fallacinol and fallacinal are minor anthraquinones, while emodin is another orange pigment found in some lichens. These compounds contribute to the chemical profile of X. parietina and have been investigated in phytochemical studies. Recent research (2023) has explored X. parietina as a natural source of anthraquinones for synthesizing pharmaceutical derivatives, such as O-methylated and acylated anthraquinones. X. parietina also produces the secondary metabolite 2-methoxy-4,5,7-trihydroxy-anthraquinone, as well as tocopherol and ergosterol.
In response, Conservative leader Kemi Badenoch accuses Farage of "manipulating" the publish by publishing "fake" figures and using an automated ticker to falsely inflate membership numbers. The following day, Farage threatens to "take some kind of action in the next couple of days", while the Reform website says the membership figure has increased to above 143,000. 27 December – Former Conservative Justice Secretary David Gauke, who is leading a review into sentencing and prison overcrowding, calls for greater use of open prisons in order to ease the pressure on closed category prisons. 29 December – Reform UK says it has notched up a further 20,000 members since the Kemi Badenoch row, reaching 150,000 members. Conservative Party allies of Kemi Badenoch reject claims she asked GB News to reduce Nigel Farage's airtime on the channel. 30 December – The King and the Prime Minister pay tribute to Jimmy Carter, following the former US president's death at the age of 100. Conor Murphy, a minister in the Northern Ireland Executive, announces he will contest the 2025 Seanad election in the Republic of Ireland for Sinn Féin, saying he will resign as a member of the Stormont Assembly if successful. 2025 New Year Honours: Those from the world of politics recognised in the New Year Honours include Sadiq Khan, Nick Gibb and Andy Street, who receive knighthoods, and Emily Thornberry, who receives a damehood.
=== Overview === Polonium can be hazardous and has no biological role. By mass, polonium-210 is around 250,000 times more toxic than hydrogen cyanide (the median lethal dose for 210Po is less than 1 microgram for an average adult (see below) compared with about 250 milligrams for hydrogen cyanide). The main hazard is its intense radioactivity (as an alpha emitter), which makes it difficult to handle safely. Even in microgram amounts, handling 210Po is extremely dangerous, requiring specialized equipment (a negative pressure alpha glove box equipped with high-performance filters), adequate monitoring, and strict handling procedures to avoid any contamination. Alpha particles emitted by polonium will damage organic tissue easily if polonium is ingested, inhaled, or absorbed, although they do not penetrate the epidermis and hence are not hazardous as long as the alpha particles remain outside the body and do not come near the eyes, which are living tissue. Wearing chemically resistant and intact gloves is a mandatory precaution to avoid transcutaneous diffusion of polonium directly through the skin. Polonium delivered in concentrated nitric acid can easily diffuse through inadequate gloves (e.g., latex gloves) or the acid may damage the gloves. Polonium does not have toxic chemical properties. It has been reported that some microbes can methylate polonium by the action of methylcobalamin. This is similar to the way in which mercury, selenium, and tellurium are methylated in living things to create organometallic compounds.
This concern is not the same as the serotonin-toxicity risk seen when MAOIs are combined with drugs that significantly inhibit serotonin reuptake or release serotonin. A classic MAOI-to-classic MAOI overlap is not expected to cause serotonin toxicity unless another serotonergic drug with clinically significant serotonin reuptake inhibition or serotonin-releasing activity is also involved. This should be distinguished from medically supervised switching between classic MAOIs, where shorter washouts, direct switches, or cautious cross-tapering have been used by some expert clinicians under close monitoring. In that context, temporary MAOI-to-MAOI overlap may have practical utility, such as reducing relapse risk or avoiding a prolonged untreated interval when changing from one MAOI to another because of adverse effects or inadequate response. Drugs described as "stimulants" are not a uniform pharmacological category and are not uniformly contraindicated with phenelzine. Modern MAOI guidance distinguishes amphetamines by dose: medium or high doses are avoided because of serotonin-releasing activity, while low-dose amphetamines are listed as a strong relative contraindication rather than an absolute contraindication. When used by experienced clinicians, they require specialist caution, reduced starting doses, slow titration, and blood-pressure monitoring. Lisdexamfetamine may be lower risk than some other amphetamine preparations because of its lower peak plasma concentration and longer time to peak concentration.
P. porrigens was once generally regarded as edible, though bland. As of 2011, it is a suspect in two outbreaks in Japan involving fatal encephalopathy. Most victims had preexisting kidney disorders. The first incident occurred in September and October 2004 across nine prefectures in Japan, documenting the sickening of 59 people and the eventual death of 17. Most of those who died had preexisting liver problems and the average age of those affected was 70. Death occurred between 13 and 29 days after the onset of symptoms, which occurred at most three weeks after consumption of the species. The second incident occurred in 2009, when a 65-year-old man who had been on hemodialysis died from acute encephalopathy after eating P. porrigens. The mechanism of action for the toxicity of P. porrigens has not been definitively established, but several possibilities have been suggested. It has been demonstrated that P. porrigens contains an unusual amino acid, Pleurocybellaziridin, which is toxic to the brain cells of rats in cell culture studies, but it has not yet been possible to definitively determine that this was the cause of the fatal encephalopathies. Other mechanisms have been suggested for P. porrigens's apparent toxicity, including the possibility that the fungus may contain toxic levels of cyanide salts. A proposed mechanism of action for the toxicity of P. porrigens has been proposed by Kawagishi, et al.
Sources: en.wikipedia.org
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.
The drug affinity complex links the peptide to serum albumin through a covalent bond. The conjugate is too large to be filtered quickly by the kidneys and is shielded from enzymatic breakdown. This extends the apparent half-life from roughly minutes to several days.
Long-term safety and any clinical benefit are unestablished. Published human data cover small groups over limited periods and focus on hormone levels rather than health outcomes. Whether prolonged elevation of growth hormone and insulin-like growth factor 1 is beneficial or harmful is an open question.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.